The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
The user noticed miniaturized hair at the front of their hairline and is not on any medication. They are concerned if this is a sign of a receding hairline or something normal.
The conversation is about finding a suitable hairbrush for diffuse thinning hair without causing separation or flattening. The user is using oral dutasteride, minoxidil foam, Nizoral, microneedling, and Pura D’or shampoo and conditioner.
The conversation highlights the general public's lack of knowledge about hair loss, with various ineffective remedies suggested, such as not wearing hats or using hair fibers. The only effective treatments mentioned for male pattern baldness are medications like minoxidil and finasteride, and hair transplants.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
The user is frustrated with ongoing hair loss despite using treatments like finasteride, dutasteride, minoxidil, RU58841, and others. They express concern over the lack of improvement in hair density and the emotional toll it takes.
The conversation humorously discusses hair loss treatments like finasteride, minoxidil, and dutasteride, referencing a "Smiling Friends" episode. It includes jokes about hair loss, AI-generated images, and the show's satire on societal perceptions of baldness.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A user discusses their experience with hair loss, noting they don't notice shedding despite using finasteride, minoxidil, and tretinoin. Others share similar experiences, suggesting that shedding varies and may not occur for everyone using these treatments.
A user discusses using a hair thickening spray similar to L'Oreal Root Touch Up, noting it provides volume and covers thinning temples but may cause hair to fall out when washed. They speculate the fallen hairs might have been loose already.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
A humorous discussion about a scalp massager used in a barber shop, with no mention of specific hair loss treatments like Minoxidil, finasteride, or RU58841. The massager is described as pleasurable but not a treatment for hair loss.
The conversation discusses hair loss struggles and treatments, including oral minoxidil, oral finasteride, and RU58841. Users share experiences and advice, suggesting options like topical minoxidil, microneedling, hair transplants, and scalp micropigmentation.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
The conversation is about a user experiencing hair thinning potentially due to excessive microneedling while using finasteride and minoxidil. Many suggest reducing microneedling frequency and considering alternative treatments like dutasteride or a hair transplant.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.